NEW YORK (GenomeWeb) – UK-based clinical decision support technology developer Congenica said today that it has raised nearly £13.3 million ($17.3 million) in an extension of its Series B funding round. The new investment brings the Series B total to £23.3 million.
Parkwalk Investors led the extension, with additional capital from new investor Digital China Health Technologies and several previous investors. Digital China Health Technologies, commonly known as DCHealth, already is a strategic partner of Congenica.
Congenica said that it will apply the new funding to accelerate international growth, particularly in China and the US. The company also is developing a new version of its flagship Sapientia genome analysis platform, which will feature more automation to support cancer treatment decisions, pharmacogenomics, and patient health management.
The company last year signed an exclusive deal with the British National Health Service to provide diagnostic decision support services to the NHS Genomic Medicine Service.
"With the formalization of our partnership with the NHS, we are now focused on accelerating the introduction of important new features to our platform. These funds will allow us to automate Sapientia, to support wider usage and reduce costs to healthcare providers, helping more clinicians provide accurate, rapid and cost-effective diagnoses to patients and their families," Congenica CEO David Atkins said in a statement.
“In addition, we can now begin to penetrate international markets," Atkins added. "The deepening of our relationship with DCHealth gives us greater insight into the needs of the China market, with the recent development of an on-premise version of our platform the most notable example."